{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:54Z","timestamp":1790949894304,"version":"4.1.0"},"reference-count":63,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"unspecified","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in RA-associated ILD (RA-ILD) remains uncertain. This systematic review and meta-analysis aimed to assess the effect of bDMARDs and tsDMARDs on ILD progression in RA, focusing on pulmonary function test (PFT) parameters\u2014forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO)\u2014and, when available, high-resolution computed tomography (HRCT) outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed and Cochrane databases were searched up to 2025 for controlled trials and observational studies, including patients with RA fulfilling the 1987 ACR or 2010 ACR\/EULAR criteria. Studies reporting longitudinal changes in PFTs or HRCT after bDMARD or tsDMARD treatment were included. Meta-analyses were conducted using the inverse variance method (RevMan V.5.4.1) for pooled estimates of FVC and DLCO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>18 observational studies including 958 patients (mean age 65 years; 57% female) were analysed. The most frequent ILD patterns were usual interstitial pneumonia (48%) and nonspecific interstitial pneumonia (40%). Data were available for rituximab (six studies), abatacept (4), JAK inhibitors (4), tumour necrosis factor (TNF) inhibitors (1) and tocilizumab (1). Pooled analysis showed no significant overall change in FVC (mean difference \u22120.85%, 95%\u2009CI \u22122.40 to 0.71; p=0.29) or DLCO (+0.79, 95%\u2009CI \u22120.30 to 1.88; p=0.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>bDMARDs and tsDMARDs appear to stabilise pulmonary function in RA-ILD, without significant differences between agents. Further prospective studies integrating PFT and HRCT endpoints are needed to better define their pulmonary safety and long-term effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006640","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:15:46Z","timestamp":1773911746000},"page":"e006640","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0225-3402","authenticated-orcid":false,"given":"St\u00e9phane","family":"Hilliquin","sequence":"first","affiliation":[{"name":"D\u00e9partement de Rhumatologie, H\u00f4pital Cochin, Assistance publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Vismara","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Rhumatologie, H\u00f4pital Cochin, Assistance publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Berlengiero","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Rhumatologie, H\u00f4pital Cochin, Assistance publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Rhumatologie, H\u00f4pital Cochin, Assistance publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026031902151143000_12.1.e006640.1","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026031902151143000_12.1.e006640.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171315"},{"key":"2026031902151143000_12.1.e006640.3","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026031902151143000_12.1.e006640.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"2026031902151143000_12.1.e006640.5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/03009742.2025.2503054","article-title":"Pulmonary function trajectories in rheumatoid arthritis-associated interstitial lung disease","volume":"54","author":"Hyldgaard","year":"2025","journal-title":"Scand J Rheumatol"},{"key":"2026031902151143000_12.1.e006640.6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X15612250"},{"key":"2026031902151143000_12.1.e006640.7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12931-021-01856-z","article-title":"Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"22","author":"Qiu","year":"2021","journal-title":"Respir Res"},{"key":"2026031902151143000_12.1.e006640.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"2026031902151143000_12.1.e006640.9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026031902151143000_12.1.e006640.10","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026031902151143000_12.1.e006640.11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003487","article-title":"Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"9","author":"Yuan","year":"2023","journal-title":"RMD Open"},{"key":"2026031902151143000_12.1.e006640.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open"},{"key":"2026031902151143000_12.1.e006640.13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026031902151143000_12.1.e006640.14","doi-asserted-by":"crossref","unstructured":"Kalyoncu U , Bilgin E , Erden A , et al . Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data. Clin Exp Rheumatol 2021. doi:10.55563\/clinexprheumatol\/9h6dtb","DOI":"10.21203\/rs.3.rs-903223\/v1"},{"key":"2026031902151143000_12.1.e006640.15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3904\/kjim.2023.207","article-title":"Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease","volume":"39","author":"Lee","year":"2024","journal-title":"Korean J Intern Med"},{"key":"2026031902151143000_12.1.e006640.16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00296-020-04545-0","article-title":"Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data","volume":"40","author":"Robles-Perez","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026031902151143000_12.1.e006640.17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","volume":"119","author":"Atienza-Mateo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026031902151143000_12.1.e006640.18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010277","article-title":"Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"2026031902151143000_12.1.e006640.19","doi-asserted-by":"crossref","first-page":"106748","DOI":"10.1016\/j.intimp.2020.106748","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d\u2019Alessandro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026031902151143000_12.1.e006640.20","first-page":"43","article-title":"Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-\u03b1 agents","volume":"35","author":"Detorakis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026031902151143000_12.1.e006640.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez177"},{"key":"2026031902151143000_12.1.e006640.22","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026031902151143000_12.1.e006640.23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040927","article-title":"Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study","volume":"11","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"J Clin Med"},{"key":"2026031902151143000_12.1.e006640.24","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026031902151143000_12.1.e006640.25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"2026031902151143000_12.1.e006640.26","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J"},{"key":"2026031902151143000_12.1.e006640.27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacol"},{"key":"2026031902151143000_12.1.e006640.28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia","volume":"02","author":"Matteson","year":"2012","journal-title":"OJRA"},{"key":"2026031902151143000_12.1.e006640.29","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026031902151143000_12.1.e006640.30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030957","article-title":"Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study","volume":"12","author":"Venerito","year":"2023","journal-title":"J Clin Med"},{"key":"2026031902151143000_12.1.e006640.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.11.035"},{"key":"2026031902151143000_12.1.e006640.32","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103070","article-title":"Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review","volume":"9","author":"Atienza-Mateo","year":"2020","journal-title":"J Clin Med"},{"key":"2026031902151143000_12.1.e006640.33","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1093\/rheumatology\/keaf314","article-title":"Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients","volume":"64","author":"Serrano-Combarro","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026031902151143000_12.1.e006640.34","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.55563\/clinexprheumatol\/h9tc57","article-title":"Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape","volume":"39","author":"Fazeli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026031902151143000_12.1.e006640.35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.rhum.2024.09.016","article-title":"Actualisation 2024 des recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie pour le diagnostic et la prise en charge des personnes souffrant de polyarthrite rhumato\u00efde","volume":"91","author":"Fautrel","year":"2024","journal-title":"Rev Rhum Ed Fr"},{"key":"2026031902151143000_12.1.e006640.36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/acr.21870","article-title":"Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis","volume":"65","author":"Lillegraven","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026031902151143000_12.1.e006640.37","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005283","article-title":"Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis","volume":"11","author":"Vermant","year":"2025","journal-title":"RMD Open"},{"key":"2026031902151143000_12.1.e006640.38","doi-asserted-by":"crossref","first-page":"01312","DOI":"10.1183\/23120541.01312-2024","article-title":"Lung involvement in rheumatoid arthritis, a prospective study","volume":"11","author":"Froidure","year":"2025","journal-title":"ERJ Open Res"},{"key":"2026031902151143000_12.1.e006640.39","first-page":"05815","article-title":"Subclinical Interstitial Lung Disease in Rheumatoid Arthritis: Implications for Early Detection and Management","volume":"S0012-3692","author":"Ormsby","year":"2025","journal-title":"Chest"},{"key":"2026031902151143000_12.1.e006640.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2016.02.010"},{"key":"2026031902151143000_12.1.e006640.41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/03009742.2024.2371658","article-title":"Prognostic factors for interstitial lung disease progression in rheumatoid arthritis: May methotrexate protect against progression","volume":"53","author":"Ekici","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"2026031902151143000_12.1.e006640.42","doi-asserted-by":"crossref","first-page":"152561","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026031902151143000_12.1.e006640.43","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026031902151143000_12.1.e006640.44","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2024.108602","article-title":"A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E)","volume":"186","author":"Higgins","year":"2024","journal-title":"Environ Int"},{"key":"2026031902151143000_12.1.e006640.45","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0011-2021"},{"key":"2026031902151143000_12.1.e006640.46","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis\u2013Associated Interstitial Lung Disease: A Prospective Cohort Study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2026031902151143000_12.1.e006640.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203160"},{"key":"2026031902151143000_12.1.e006640.48","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1007\/s10067-021-05808-2","article-title":"Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: a meta-analysis","volume":"40","author":"Xie","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026031902151143000_12.1.e006640.49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208216"},{"key":"2026031902151143000_12.1.e006640.50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28756"},{"key":"2026031902151143000_12.1.e006640.51","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210790","article-title":"Characterization of human FDCs reveals regulation of T cells and antigen presentation to B cells","volume":"218","author":"Heesters","year":"2021","journal-title":"J Exp Med"},{"key":"2026031902151143000_12.1.e006640.52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1512600113"},{"key":"2026031902151143000_12.1.e006640.53","doi-asserted-by":"publisher","DOI":"10.1002\/art.20765"},{"key":"2026031902151143000_12.1.e006640.54","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","article-title":"Lessons for rituximab therapy in patients with rheumatoid arthritis","volume":"2","author":"Garcia-Montoya","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2026031902151143000_12.1.e006640.55","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1513\/AnnalsATS.202203-267OC","article-title":"The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis","volume":"19","author":"Copeland","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026031902151143000_12.1.e006640.56","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-019-0943-2","article-title":"Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study","volume":"19","author":"Chan","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026031902151143000_12.1.e006640.57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-025-03617-5","article-title":"Meta-analysis identifies the major impact of patient classification on the ACPA association with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"27","author":"Kaczmarczyk","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026031902151143000_12.1.e006640.58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200863"},{"key":"2026031902151143000_12.1.e006640.59","first-page":"1417","article-title":"Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study","volume":"41","author":"Hilliquin","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026031902151143000_12.1.e006640.60","first-page":"455","article-title":"Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis","volume":"38","author":"Alemao","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026031902151143000_12.1.e006640.61","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3390\/jcm8122038","article-title":"Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians","volume":"8","author":"Bendstrup","year":"2019","journal-title":"JCM"},{"key":"2026031902151143000_12.1.e006640.62","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s10067-020-04938-3","article-title":"Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER","volume":"39","author":"Ferrazza","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026031902151143000_12.1.e006640.63","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1513\/AnnalsATS.202410-1048OC","article-title":"Quantitative Computed Tomography Measures of Lung Fibrosis and Outcomes in the National Lung Screening Trial","volume":"22","author":"Wang","year":"2025","journal-title":"Ann Am Thorac Soc"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:15:54Z","timestamp":1773911754000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,19]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006640"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006640","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}